Colgate-Palmolive Stock Should Do Better in 2026, but That's Not Saying Much

Colgate-Palmolive shares have fallen roughly 15% year-to-date in 2025, but the company’s fundamentals remain intact: it has accelerated product development and has met or exceeded its 3–5% organic sales-growth target for 24 consecutive quarters. Management’s strong free-cash-flow generation (mid-teens percent of sales over the past five years), a 63-year streak of dividend increases, and a $5 billion buyback program support the valuation, while AI-driven efficiency initiatives and a potential easing of inflation—benefiting middle-income consumers—could help drive a measured rebound; however, any recovery is likely to be steady rather than a high-growth “story stock” surge.

Analysis

Colgate-Palmolive shares have underperformed in 2025, falling roughly 15% year-to-date despite management reporting accelerated product development and a 24-quarter streak of meeting or exceeding its organic sales-growth objective of 3%–5%. That persistent top-line consistency signals demand stability across the core portfolio even as the broader consumer staples group has been out of favor.

The company’s cash-generation profile supports patient investors: management has delivered mid-teens free cash flow as a percentage of sales over the past five years, maintained a 63-year streak of dividend increases and paid dividends for the 130th consecutive year in 2025, and authorized a $5 billion share-repurchase program. Sell-side commentaries from Goldman Sachs and Morgan Stanley cited a relatively healthy middle-income consumer and potential AI-driven efficiency gains, though the article cautions AI benefits may be slow to translate into equity re-rating.

Macro and input-cost dynamics are the primary near-term sensitivities: cooling inflation and falling raw-material costs would improve margins and make a measured rebound more likely, while persistent consumer weakness or elevated commodity costs would constrain upside. Investors should therefore expect a steady, income-driven recovery rather than a rapid, growth-stock style rerating and monitor execution on new product rollouts and buyback deployment closely.

Key Decisions for Investors

• Consider selective accumulation for income-focused portfolios given the 63-year dividend-growth streak, mid-teens FCF margin history, and the $5 billion buyback program, but size positions conservatively because upside is likely to be gradual rather than a rapid rerating
• Monitor three lead indicators — raw-material/inflation trends, middle-income consumer spending (per Goldman Sachs), and execution on accelerated product launches (sustained organic growth at 3%–5%) — and increase exposure only if these signals show consistent improvement
• If near-term downside protection is required, limit exposure or use tactical hedges until there is clear evidence of margin recovery or meaningful buyback activity, and avoid allocating to Colgate-Palmolive when seeking high-growth, AI-style returns